|
시장보고서
상품코드
2016390
남성 성선기능저하증 시장 보고서 : 치료법별, 약물전달별, 용도별, 지역별(2026-2034년)Male Hypogonadism Market Report by Therapy Type, Drug Delivery, Application, and Region 2026-2034 |
||||||
세계의 남성 성선기능저하증 시장 규모는 2025년에 40억 달러에 달했습니다. 향후 IMARC Group은 2034년까지 시장 규모가 59억 달러에 달하며, 2026-2034년에 CAGR 4.14%로 성장할 것으로 예측하고 있습니다. 남성의 테스토스테론 결핍증 유병률의 현저한 증가, 남성 성선기능저하증 치료 옵션에 대한 환자층의 인식 증가, 건강 인식의 향상 등이 시장을 주도하는 주요 요인으로 작용하고 있습니다.
남성 성선기능저하증은 고환이 충분한 테스토스테론을 생산하지 못해 근육의 성장 부족, 체모의 성장 장애, 유방의 발달, 목소리의 저음화 등이 나타나는 상태를 말합니다. 이 질환은 남성의 테스토스테론 또는 정자 생산 부족이 특징입니다. 그 원인은 고환과 관련된 장애(원발성 성선기능저하증) 또는 시상하부-뇌하수체 축과 관련된 장애(이차성 성선기능저하증)에 기인합니다. 성선기능저하증 환자는 고환의 문제나 시상하부 및 뇌하수체에 영향을 미치는 장애로 인해 다양한 장기의 기능장애와 더불어 삶의 질 저하를 겪을 수 있습니다. 남성의 성선기능저하증은 유전적 또는 후천적으로 발생할 수 있으며, 호르몬 불균형, 약물, 노화 등으로 인해 발생할 수 있습니다. 일부 선천성 효소 이상은 전신에 다양한 정도의 안드로겐 저항성을 유발하는 원인이 됩니다. 성선기능저하증은 60세 이상 남성에게 가장 많이 나타나며, 성선기능저하증으로 인한 증상과 징후는 연령에 따라 다릅니다.
남성 성선기능저하증 시장 동향:
세계 시장은 주로 남성의 테스토스테론 결핍 유병률의 현저한 증가와 불임률의 증가에 의해 주도되고 있습니다. 이는 비만과 당뇨병을 포함한 만성 생활습관병의 발생률 증가에 기인한 것으로 추정됩니다. 이에 따라 남성 성선기능저하증에 걸리기 쉬운 고령 인구의 증가도 시장을 촉진하는 요인으로 작용하고 있습니다. 또한 남성 성선기능저하증 치료 옵션에 대한 환자들의 인식이 높아진 것도 중요한 성장 요인으로 작용하고 있습니다. 많은 국가의 정부 기관은 테스토스테론 대체요법(TST)을 포함한 성선기능저하증 치료법에 대한 인식 개선 활동을 추진하고 있습니다. 그러나 외용 테스토스테론 호르몬 주사에 따른 심각한 부작용은 남성 성선기능저하증 시장의 성장을 크게 저해하는 요인으로 작용하고 있습니다. 한편, 임상시험의 증가와 새로운 치료법의 등장으로 인해 예측 기간 중 남성 성기능 저하증 시장은 새로운 성장 기회를 창출할 것으로 예상됩니다. 여기에 더해, 세계 의료 인프라 구축의 지속적인 기술 발전은 시장에 밝은 전망을 가져다주고 있습니다. 기타 시장 확대에 기여하는 요인으로는 급속한 도시화, 건강에 대한 인식 증가, 의료비 상승, 활발한 연구개발(R&D) 활동 등을 꼽을 수 있습니다.
이 보고서에서 답변하는 주요 질문
- 지금까지 글로벌 남성 성선기능저하증 시장은 어떤 추세를 보였을까? 그리고 향후 수년간 어떤 추세를 보이는가?
- 세계의 남성 성선기능저하증 시장 촉진요인, 제약 요인 및 기회는 무엇인가?
- 주요 지역 시장은 어디인가?
- 가장 매력적인 남성 성기능 저하증 시장을 형성하는 국가는 어느 국가인가?
- 치료법별로 보면 시장은 어떻게 구분되는가?
- 약물전달 방법별 시장 현황은?
- 용도에 따른 시장 내역은?
- 세계의 남성 성선 기능 저하증 시장의 경쟁 구조는 무엇인가?
- 세계의 남성 성선기능저하증 시장의 주요 플레이어/기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 개요
제4장 서론
제5장 세계의 남성 성선기능저하증 시장
제6장 시장 내역 : 치료법별
제7장 시장 내역 : 약물전달별
제8장 시장 내역 : 용도별
제9장 시장 내역 : 지역별
제10장 촉진요인·억제요인·기회
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
제13장 가격 분석
제14장 경쟁 구도
KSA 26.05.07The global male hypogonadism market size reached USD 4.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 5.9 Billion by 2034, exhibiting a growth rate (CAGR) of 4.14% during 2026-2034. A considerable rise in the prevalence of testosterone deficiency in males, the rising awareness of male hypogonadism treatment choices among the patient population, and increasing health consciousness represent some of the key factors driving the market.
Male hypogonadism is a medical condition in which the testes fail to produce enough testosterone, leading to a lack of muscle growth, impaired hair growth, breast development, as well as a lack of deepening of the voice. The medical condition is characterized by a lack of testosterone or spermatozoa production in men. It is caused owing to the disorder related to the testes (primary hypogonadism) or the hypothalamic-pituitary axis (secondary hypogonadism). An individual with hypogonadism may suffer from a variety of organ dysfunctions as well as a reduction in quality of life since it originates from a testicular problem or disorder that affects the hypothalamus and pituitary gland. Hypogonadism in men can be genetic or acquired, caused by hormonal imbalances, medications or aging. Several congenital enzyme abnormalities are responsible for causing different degrees of androgen resistance throughout the body. Hypogonadism is most common in men over the age of 60, and the symptoms and indications of the deficiency vary accordingly.
MALE HYPOGONADISM MARKET TRENDS:
The global market is primarily driven by a considerable rise in the prevalence of testosterone deficiency in males, along with the growing infertility rates. This can be attributed to the increasing incidences of chronic lifestyle disorders, including obesity and diabetes. In line with this, the expanding geriatric population that is more susceptible to developing male hypogonadism is also providing an impetus to the market. Moreover, the rising awareness of male hypogonadism treatment choices among the patient population is also acting as a significant growth-inducing factor. Government bodies across several countries are promoting awareness of hypogonadism treatment methods, including testosterone replacement therapy (TST). However, severe adverse reactions associated with external testosterone hormone injections are acting as a significant growth-restraining factor for the male hypogonadism market. Conversely, the increasing number of clinical trials and the emergence of new treatment options are expected to create new male hypogonadism market opportunities for growth during the forecast period. Apart from this, continual technological advancements in the development of medical infrastructure on the global level are creating a positive outlook for the market. Some of the other factors contributing to the market include rapid urbanization, increasing health consciousness, high medical expenditure and extensive research and development (R&D) activities.
KEY MARKET SEGMENTATION:
Therapy Type Insights
- Testosterone Replacement Therapy
- Gonadotropin-Releasing Hormones Therapy
Drug Delivery Insights
- Topical Gels
- Injectables
- Transdermal Patches
- Others
Application Insights
- Kallmann Syndrome
- Klinefelters Syndrome
- Pituitary Disorders
- Others
Regional Insights
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for male hypogonadism. Some of the factors driving the North America male hypogonadism market include the growing geriatric population, rising prevalence of sedentary lifestyle and related medical conditions, increasing number of clinical trials, the emergence of new treatment options, etc.
COMPETITIVE LANDSCAPE:
The report has also provided a comprehensive analysis of the competitive landscape in the global male hypogonadism market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AbbVie Inc, Endo International Plc, Ferring Holding S.A, Grunenthal GmbH, Lilly USA, LLC (Eli Lilly and Company), Pfizer Inc, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
KEY QUESTIONS ANSWERED IN THIS REPORT
- How has the global male hypogonadism market performed so far and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global male hypogonadism market?
- What are the key regional markets?
- Which countries represent the most attractive male hypogonadism markets?
- What is the breakup of the market based on the therapy type?
- What is the breakup of the market based on the drug delivery?
- What is the breakup of the market based on the application?
- What is the competitive structure of the global male hypogonadism market?
- Who are the key players/companies in the global male hypogonadism market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Male Hypogonadism Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Therapy Type
- 6.1 Testosterone Replacement Therapy
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Gonadotropin-Releasing Hormones Therapy
- 6.2.1 Market Trends
- 6.2.3 Market Forecast
7 Market Breakup by Drug Delivery
- 7.1 Topical Gels
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Injectables
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Transdermal Patches
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by Application
- 8.1 Kallmann Syndrome
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Klinefelters Syndrome
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Pituitary Disorders
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 Drivers, Restraints, and Opportunities
- 10.1 Overview
- 10.2 Drivers
- 10.3 Restraints
- 10.4 Opportunities
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 AbbVie Inc
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Endo International Plc
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Ferring Holding S.A
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.4 Grunenthal GmbH
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 SWOT Analysis
- 14.3.5 Lilly USA, LLC (Eli Lilly and Company)
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.6 Pfizer Inc
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.6.4 SWOT Analysis
- 14.3.7 Sun Pharmaceutical Industries Limited
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.7.4 SWOT Analysis
- 14.3.8 Teva Pharmaceutical Industries Ltd
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.1 AbbVie Inc
